In Brief: Alzheimer's drug proves ineffective for delirium

As many as 80% of patients admitted to intensive care units develop delirium, a condition that involves confusion and rapid mental changes (such as alternating between lethargy and agitation). Delirium worsens prognosis and increases the amount of time patients spend in the hospital. Moreover, there's little evidence to show that the standard drug treatment for delirium — antipsychotics or benzodiazepines to control agitation — does any good.

Preliminary research suggested that cholinesterase inhibitors, normally prescribed for patients with Alzheimer's disease, might improve mental functioning in patients with delirium. However, the first large randomized controlled study testing one of these drugs, rivastigmine (Exelon), found that the drug not only worsened delirium in critically ill patients, but also extended hospital stays. Investigators stopped the trial early because they also found that more patients died while taking rivastigmine than while taking a placebo.

To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »